Memphasys Limited (ASX:MEM)
Australia · Delayed Price · Currency is AUD 0.0040
0.00 (0.00%)
Aug 1, 2025, 10:30 AM AEST
Memphasys Company Description
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.
The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes.
It also provides RoXsta, a rapid oxidative stress assay; and AI-Port. In addition, the company offers ambient temperature storage product for human sperm.
Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Memphasys Limited
| Country | Australia |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | David Ali |
Contact Details
Address: 34 Richmond Road Homebush, New South Wales 2140 Australia | |
| Phone | 61 2 8415 7300 |
| Website | memphasys.com |
Stock Details
| Ticker Symbol | MEM |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000MEM5 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Ali | Chief Executive Officer, MD and Executive Director |
| Pablo Neyertz | Director of Finance |
| Associate Prof. Hassan Bakos | Director of Operations |
| Prof. R. John Aitken Ph.D., ScD FRSE | Scientific Director |
| Andrew William Metcalfe B.Bus., C.P.A., CPA, DipAppCorpGov, FCIS, FGIA, MA | Company Secretary |